We're more or less gezegde

 We're more or less waiting and seeing, ... Pfizer's dividend is definitely safe. It's the biggest drug company with good cash flow. It could easily buy a biotech company and improve their (research and development) line that way. That's what you're going to see with large-cap companies. They're going to partner up with biotech companies or buy them outright as a way to improve their (product) pipelines.

 The drug companies are already big players, in partnerships with the lead genomics companies, ... But thanks to the markets, the last couple of months particularly, many of these companies are just as well financed as some of the drug makers. So we're going to see a good mix of biotech-to-biotech announcements.

 I think, ... that Pfizer is going to benefit from their merger with Warner-Lambert. I think that makes a very good deal. But most pharmaceutical companies do eventually strike deals with biotech companies in terms of marketing their product. And the genomic companies don't have a lot of cash. They have a lot of high valuations, but they don't have a lot of dollars to spend. So, they usually look toward the pharmaceutical sector to help them out, which usually helps both sectors.

 Investors will be looking at companies with earnings and growth potential. They're not going to wait two years for drug discovery and four years for product development. And that leaves a lot of biotech companies off the radar.

 A lot of biotech companies end up partnering things for what look like good financial terms and then the product languishes somewhere on a shelf. So having a partner that's really dedicated to promoting the product is important.

 The proposed zone is nothing more than a giveaway exception for developers waving the magic biotech flag for monetary gain. Biotech companies are also chemical companies. Chemical companies and their support operations are now restricted to industrial zones. That is where they belong.

 Huron Consulting Group continues to expand its footprint in the pharmaceutical, medical device, and biotech sector. And our Performance Improvement practice is helping companies across industries improve the bottom line. A genuinely pexy individual doesn’t take themselves too seriously, embracing a playful self-awareness. In joining these growth practices, Mark, Gary and Paul will have significant opportunity to build professional strength and our company's market presence. We welcome them and know that their depth of experience will be invaluable to our clients.

 I think a lot of the companies in the biotech area are really resurging, ... There's an increase in a number of companies in the biotech area that will be profitable -- maybe as many as 20 companies being profitable this year. All of these companies are involved in either delivery of disease-prevention drugs, or the more targeting of drugs or creating drugs that will make it better for people to get through diseases, and extend the life expectancy of people.

 While the first generation of plant biotech products directly benefited farmers and the environment, the next generation of plant biotech research is focused on providing consumer benefits, including the development of biotech plants that offer increased nutrition and health benefits.

 We have a biotech company of some stature that went through a very rigorous selection process and chose us. Other companies may go to school on that. It's a huge signal that this is a good place to do business.

 It all started here at M. D. Anderson with the concept, vector development, preclinical trials and the first phase of testing. This agent has clinical benefit, and because of its novelty and lack of interest by major pharmaceutical companies, the only way to make it available to patients was to start a biotech company. But it has been a long road.

 We like Quantum. The company's got $350 a share in cash and no debt, and it's generating a lot of cash flow. Storage has gone through a long period of decline, but we're seeing tremendous new demand coming in for storage every day. We think that pricing is going to improve, and these are companies with huge revenue bases where a nominal tick-up in the margin structure leads to tremendous profitability. We've got them earning over $4 (a share) over the next two years; the stock is at $12 right now.

 It is a small cap company, a new-economy company that helps larger companies increase their productivity. Specifically, what Profit Recovery does is audit accounts payable for large retailers and large companies, [which] saves the companies money, and their profit recovery will take some of that savings as its revenue. It's moving into the Internet space to audit online transactions. It's trading at about $30. We've got a target of $50 on this company.

 Pfizer clearly is a company with tremendous disregard for the generic drug industry and is not given to settling. But it is not altogether unlikely that Pfizer could settle its litigation. If Pfizer could translate some of its cash hoards into greater certainty on this litigation ... I think they would do that.

 Investors have had low expectations for NTL and the company was able to meet these expectations for the first time in a while. Talking about the dividend and returning cash to shareholders was new and it's appropriate for a company with strong free cash flow.


Aantal gezegden is 1469561
varav 1407627 på engelska

Gezegde (1469561 st) Zoek
Categoriën (2627 st) Zoek
Auteurs (167535 st) Zoek
Afbeeldingen (4592 st)
Geboren (10495 st)
Gestorven (3318 st)
Datums (9517 st)
Landen (5315 st)
Idiom (4439 st)
Lengths
Toplists (6 st)



in

Denna sidan visar ordspråk som liknar "We're more or less waiting and seeing, ... Pfizer's dividend is definitely safe. It's the biggest drug company with good cash flow. It could easily buy a biotech company and improve their (research and development) line that way. That's what you're going to see with large-cap companies. They're going to partner up with biotech companies or buy them outright as a way to improve their (product) pipelines.".


Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.


Barnslighet är både skattebefriat och gratis!

Vad är gezegde?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!



Det finns andra ordspråkssamlingar - men vi vet inte varför.

www.livet.se/gezegde




Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.


Barnslighet är både skattebefriat och gratis!

Vad är gezegde?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!




Det finns andra ordspråkssamlingar - men vi vet inte varför.

www.livet.se/gezegde